Local response to microneedle-based influenza immunization in the skin

mBio

Volumn 3, Issue 2, 2012, Pages

  Martin, Maria del Pilar ^a   Weldon, William C ^a   Zarnitsyn, Vladimir G ^b   Koutsonanos, Dimitrios G ^a   Akbari, Hamed ^a   Skountzou, Ioanna ^a   Jacob, Joshy ^a   Prausnitz, Mark R ^b   Compans, Richard W ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Georgia Institute of Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VIRUS; INNATE IMMUNITY; MICRONEEDLE BASED INFLUENZA VACCINATION; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN; VACCINATION;

MURINAE; MUS; ORTHOMYXOVIRIDAE;

EID: 84860524534     PISSN: None     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00012-12     Document Type: Article

References (46)

1. Monto AS. 2010. Seasonal influenza and vaccination coverage. Vaccine 28(Suppl. 4):D33-D44.
2. Ampofo WK, et al. 2012. Improving influenza vaccine virus selection. Report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza Other Respi. Viruses, 6(2): 142-152.
3. Hannoun C, Megas F, Piercy J. 2004. Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 103(1-2):133-138.
4. Coudeville L, et al. 2010. Relationship between haemagglutinationinhibiting antibody titres and clinical protection against influenza: development and application of a Bayesian random-effects model. BMC Med. Res. Methodol. 10:18.
5. Block SL, Toback SL, Yi T, Ambrose CS. 2009. Efficacy of a single dose of live attenuated influenza vaccine in previously unvaccinated children: a post hoc analysis of three studies of children aged 2 to 6 years. Clin. Ther. 31(10):2140-2147.
6. Ambrose CS, Levin MJ, Belshe RB. 2011. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respi Viruses 5(2):67-75.
7. Centers for Disease Control and Prevention (CDC). 2011. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). Am. J. Transplant. 11(10):2250-2255.
8. Ansaldi F, Durando P, Icardi G. 2011. Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement. Expert Opin. Biol. Ther. 11(3):415-427.
9. ®) administered by intradermal and intramuscular route in healthy adults. Vaccine 29(34):5666-5674.
10. Teunissen MB, Haniffa M, Collin MP. 2012. Insight into the immunobiology of human skin and functional specialization of skin dendritic cell subsets to innovate intradermal vaccination design. Curr. Top. Microbiol. Immunol. 351:25-76.
11. Di Meglio P, Qin JZ, Nickoloff BJ, Prausnitz MR, Kang SM. 2009. Skin immune sentinels in health and disease. Nat. Rev. Immunol. 9(10): 679-691.
12. Weldon WC, et al. 2011. Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity. Clin. Vaccine Immunol. 18:647-654.
13. Koutsonanos DG, et al. 2009. Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS One 4(3):e4773.
14. Quan FS, Kim YC, Compans RW, Prausnitz MR, Kang SM. 2010. Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J. Control. Release 147(3):326-332.
15. Song JM, et al. 2010. Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. Antiviral Res. 88(2):244-247.
16. Fernando GJ, et al. 2010. Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. PLoS One 5(4):e10266.
17. Pulendran B. 2007. Tolls and beyond-many roads to vaccine immunity. N. Engl. J. Med. 356(17):1776-1778.
18. Pulendran B. 2004. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol. Rev. 199:227-250.
19. Griffiths CE, Dearman RJ, Cumberbatch M, Kimber I. 2005. Cytokines and langerhans cell mobilisation in mouse and man. Cytokine 32(2): 67-70.
20. Caux C, et al. 2002. Regulation of dendritic cell recruitment by chemokines. Transplantation 73(1 Suppl.):S7-S11.
21. Zhu M, Oishi K, Lee SC, Patterson PH. 2001. Studies using leukemia inhibitory factor (LIF) knockout mice and a LIF adenoviral vector demonstrate a key anti-inflammatory role for this cytokine in cutaneous inflammation. J. Immunol. 166(3):2049-2054.
22. Vermaelen KY, Carro-Muino I, Lambrecht BN, Pauwels RA. 2001. Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. J. Exp. Med. 193(1):51-60.
23. El Marsafy S, Bagot M, Bensussan A, Mauviel A. 2009. Dendritic cells in the skin-potential use for melanoma treatment. Pigment. Cell. Melanoma Res. 22(1):30-41.
24. Sparber F, Tripp CH, Hermann M, Romani N, Stoitzner P. 2010. Langerhans cells and dermal dendritic cells capture protein antigens in the skin: possible targets for vaccination through the skin. Immunobiology 215(9-10):770-779.
25. Kim YC, Prausnitz MR. 2011. Enabling skin vaccination using new delivery technologies. Drug. Deliv. Transl. Res. 1(1):7-12.
26. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. 2004. Dose sparing with intradermal injection of influenza vaccine. N. Engl. J. Med. 351(22):2295-2301.
27. Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv. Drug Deliv. Rev., in press.
28. Koutsonanos DG, et al. 2011. Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination. J. Infect. Dis. 204(4):582-591
29. Bal SM, Ding Z, van Riet E, Jiskoot W, Bouwstra JA. 2010. Advances in transcutaneous vaccine delivery: do all ways lead to Rome? J. Control. Release 148(3):266-282.
30. Cumberbatch M, Dearman RJ, Griffiths CE, Kimber I. 2000. Langerhans cell migration. Clin. Exp. Dermatol. 25(5):413-418.
31. Cumberbatch M, Dearman RJ, Kimber I. 1997. Langerhans cells require signals from both tumour necrosis factor alpha and interleukin 1 beta for migration. Adv. Exp. Med. Biol. 417:125-128.
32. Arnoldi J, Moll H. 1998. Langerhans cell migration in murine cutaneous leishmaniasis: regulation by tumor necrosis factor alpha, interleukin-1 beta, and macrophage inflammatory protein-1 alpha. Dev. Immunol. 6(1-2):3-11.
33. Croker BA, et al. 2011. Neutrophils require SHP1 to regulate IL-1beta production and prevent inflammatory skin disease. J. Immunol. 186(2): 1131-1139.
34. Stoitzner P, Pfaller K, Stössel H, Romani N. 2002. A close-up view of migrating Langerhans cells in the skin. J. Invest. Dermatol. 118(1): 117-125.
35. Shortman K, Liu YJ. 2002. Mouse and human dendritic cell subtypes. Nat. Rev. 2(3):151-161.
36. Henri S, et al. 2001. The dendritic cell populations of mouse lymph nodes. J. Immunol. 167(2):741-748.
37. Larsen CP, et al. 1994. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J. Immunol. 152(11):5208-5219.
38. Morefield GL, et al. 2005. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23(13): 1588-1595.
39. Bachmann MF, Jennings GT. 2010. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. 10(11):787-796.
40. Hem SL, Hogenesch H. 2007. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev. Vaccines 6(5):685-698.
41. Sen D, Forrest L, Kepler TB, Parker I, Cahalan MD. 2010. Selective and site-specific mobilization of dermal dendritic cells and Langerhans cells by Th1- and Th2-polarizing adjuvants. Proc. Natl. Acad. Sci. U. S. A. 107(18): 8334-8339.
42. Caminschi I, Lahoud MH, Shortman K. 2009. Enhancing immune responses by targeting antigen to DC. Eur. J. Immunol. 39(4):931-938.
43. Martin MDP, et al. 2010. Adjuvanted influenza vaccine administered intradermally elicits robust long-term immune responses that confer protection from lethal challenge. PLoS One 5(5):e10897.
44. Compans RW. 1974. Hemagglutination-inhibition: rapid assay for neuraminic acid-containing viruses. J. Virol. 14(5):1307-1309.
45. Barclay D, et al. 2008. A simple, rapid, and convenient Luminex compatible method of tissue isolation. J. Clin. Lab. Anal. 22(4):278-281.
46. Ortner U, et al. 1996. An improved isolation method for murine migratory cutaneous dendritic cells. J. Immunol. Methods 193(1):71-79.